SUMMA Bio-Solutions

Summa Bio-Solutions is a commercially driven biotechnology company focused on developing cellular medical solutions for degenerative conditions in both humans and animals. Formed by its parent company, Tithon Biotech, the company utilizes proprietary technologies such as nPSC (new Pluripotent Stem Cell) isolation from peripheral blood and AD-MSC-CM (Adipose Derived Mesenchymal Stem Cell Conditioned Medium). Its platform supports stem cell isolation, conditioned medium production, tissue engineering, and the development of 3D organoids for regenerative medicine. Summa is currently advancing its lead product candidate, AD-MSC-CM, through pre-clinical testing with plans for clinical pilot studies under FDA oversight. The company is headquartered in Fort Worth, Texas, and maintains research collaborations with academic institutions to advance its pipeline of regenerative therapies.